Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Juvederm Users: Cosmetic Dermatologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
Sunil DhawanNovember 19, 2007
CRx-191 - an intriguing combination product
Analysis of: CombinatoRx Announces Initiation of Phase 2a Clinical Study of CRx-191 in Psoriasis | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
CombinatoRx new combination product- CRx-191 is intriguing in that it combines a topical steroid with nortryptiline to minimize the negative effects of the steroid and make it more potent. This would be useful in that higher potency topical steroids are more effective, but cause more thinning of the...
Sunil DhawanNovember 12, 2007
Stifel and Allergan collaboration very positive
Analysis of: Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc. to Expand and Strengthen Dermatologic Product Offering | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recently announced collaboartion between Stiefel and Allergan in regards to Tazorac is very positive. Stiefel needs this molecule to put into different dosage forms, and in combination with its existing products espoecially Duac, etc. Their current acne product line is strong, but this will solodify...
October 31, 2007
GENETECH BACKTRACKS ON ITS DECISION TO LIMIT AVASTIN FOR WET MACULAR DEGERNATION
Analysis of: Genentech revisits plan for Avastin | www.sfgate.com
Author: GLG Expert Contributor
In the two weeks since Genetech made its announcement that it would limit the availability of Avastin to ophthalmologists for use in treating wet macular degeneration the outcry from patients, ophthalmologists, politicians, and the American Academy of OPhthalmology has been so great that Genetech is...
October 29, 2007
American Academy of Ophthalmology Issues Press Statement Criticizing Genentech's Decision to Limit Avastin Availability for the Treatment of Wet Macular Degeneration
Analysis of: Ophthalmologists Concerned About AMD Patients’ Access To Avastin | aao.org
Author: GLG Expert Contributor
The American Academy of Ophthalmology said the recent decision by Genentech to limit availability of Avastin (bevacizumab) to compounding pharmacies could have a significant negative impact on the care of patients with age-related macular degeneration [AMD]. Dr. Charles Wilkinson, president of the AAO,...
October 22, 2007
BREAKING NEWS: GENETECH TO RESTRICT THE AVAILABILITY OF AVASTIN IN ORDER TO LIMIT ITS USE OVER ITS MORE EXPENSIVE FDA APPROVED MEDICINE (LUCENTIS) FOR WET MACULAR DEGENERATION
Analysis of: Genentech to cease supplying bevacizumab to compounding pharmacies | www.osnsupersite.com
Author: GLG Expert Contributor
Genentech, Inc.  is suspending sales of Avastin (bevacizumab) to compounding pharmacies in the United STates, in an effort to curb its non approved use for wet macular degenration. Recently, ophthalmologists have begun using the antiangiogenic cancer drug off-label to treat retinal neovascularization...
Sunil DhawanOctober 8, 2007
Abbotts ABT-874 shows good results in Psoriasis
Analysis of: Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Abbotts ABT-874 monoclonal antibody for psoriasis shows impressive results in the phase 2 trial. The results were up to 90% of patients achieving at least 75% reduction in their psoriasis. These results are as good or better than those with Remicade the most effective biologic for psoriasis currently....
Sunil DhawanSeptember 28, 2007
Relieva results in recent clinical trial for eczema
Analysis of: Relieva Exceeds Expectations In Recent Clinical Trial For Eczema (Atopic Dermatitis) | www.medicalnewstoday.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recent results for a trial of Relieva in atopic dermatitis or eczema, a cream containing a homeopathic compound, were positive by a report from the company. The study sample was small, and the trial was open label. Generally these trials have a larger number of patients, and are blinded. Also it...
September 24, 2007
Inurance reimbursement for MWL body contouring
Analysis of: Bariatric surgery - possible treatment for type 2 diabetes mellitus | www.news-medical.net
Author: GLG Expert Contributor
I have seen a trend of decreased reimbursements in my practice with post MWL body contouring.  These patients are plagued with complications due to their malabsorption.  Wound healing and seroma formations are issues that are encountered close to 100% of all MWL patients who undergo elective...
September 24, 2007
Physician house calls
Analysis of: The New York Times | www.nytimes.com
Author: GLG Expert Contributor
House calls for physicians is a growing area in the primary care fields since the reimbursements are so low for the services provided at their clinics.  Physicians can make 10 times the amout if they do house calls as compared to seeing patients in the office.  so clearly this is an expanding...
September 24, 2007
OMEGA 3 FATTY ACIDS CAN HOLD PROMISE IN TREAMENT OF MANY EYE DISEASES
Analysis of: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth | www.pnas.org
Author: GLG Expert Contributor
Omega-3 supplementation could be a useful strategy for protecting against retinopathy of prematurity (ROP), say Swedish investigators. In the study, mice with retinopathy were fed food enriched with either omega-3 or omega-6. Mice that ate omega-3 initially lost fewer retinal blood vessels than mice...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next71 to 80 of 188

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747